S Anderson
YOU?
Author Swipe
View article: P422 How achievable are the STRIDE-II treatment targets in real-world practise and do they affect outcome?
P422 How achievable are the STRIDE-II treatment targets in real-world practise and do they affect outcome? Open
Background The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative provides recommendations on treatment targets for patients with Crohn’s disease (CD). The Simple Endoscopic Score for CD (SES-CD) is a validated…
View article: P723 Therapeutic thresholds for golimumab serum concentrations during induction and maintenance: Results from the GO-LEVEL study
P723 Therapeutic thresholds for golimumab serum concentrations during induction and maintenance: Results from the GO-LEVEL study Open
Background The exposure–response relationship associated with the use of golimumab for UC has been previously demonstrated in the PURSUIT trial programme. A significant association between serum golimumab concentrations (SGC) and favourabl…
View article: Low FODMAP diet & prebiotic β-galactooligosaccharides improve irritable bowel syndrome and response to low FODMAP is predicted by urine and faecal metabolites: a randomised controlled trial
Low FODMAP diet & prebiotic β-galactooligosaccharides improve irritable bowel syndrome and response to low FODMAP is predicted by urine and faecal metabolites: a randomised controlled trial Open
Low FODMAP diet & prebiotic β-galactooligosaccharides improve irritable bowel syndrome and response to low FODMAP is predicted by urine and faecal metabolites: a randomised controlled trial - Volume 79 Issue OCE1
View article: Prebiotic B-Galacto-oligasaccharide supplementation of the low FODMAP diet improves symptoms of irritable bowel syndrome but does not prevent diet induced decline in bifidobacteria: a randomised controlled trial
Prebiotic B-Galacto-oligasaccharide supplementation of the low FODMAP diet improves symptoms of irritable bowel syndrome but does not prevent diet induced decline in bifidobacteria: a randomised controlled trial Open
Prebiotic B-Galacto-oligasaccharide supplementation of the low FODMAP diet improves symptoms of irritable bowel syndrome but does not prevent diet induced decline in bifidobacteria: a randomised controlled trial - Volume 76 Issue OCE4